A retrospective study comprising of 838 gastric cancer patients from all stages demonstrated that the best survival outcomes were observed for patients with HER2-negative intestinal-type gastric cancer, whereas the worst survival outcomes were for those with HER2-positive diffuse-type gastric cancer [33]. This evidence concerns the gene ERBB2 and gastric cancer.